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Abstract
The receptor of advanced glycation endproducts (RAGE) is a
multiligand receptor that upon activation causes sustained
activation of multiple inflammatory pathways. Recent evidence,
summarized in a review by Bopp and colleagues in this issue of
Critical Care, has implicated RAGE as a potential therapeutic
target in sepsis. Here, we discuss several open issues that need to
be addressed before anti-RAGE strategies can enter the sepsis
clinical trial arena.
In a review in this issue of Critical Care, Bopp and colleagues
[1] summarize current knowledge on the receptor of
advanced glycation endproducts (RAGE) and its potential as
a new therapeutic target in sepsis. RAGE is expressed in
many cell types involved in the innate immune system and is
able to recognize a wide range of endogenous molecules that
are released during various conditions of inflammation and/or
injury. Collectively, these endogenous molecules, which warn
the host of imminent danger, have been called alarmins or
danger-associated molecular patterns [2]. An important
example of an alarmin and an established ligand for RAGE
with relevance for sepsis is high-mobility group box 1
(HMGB1) [3].
Activation of RAGE results in sustained activation of nuclear
factor-kappa B (NF-κB), thereby converting transient pro-
inflammatory responses into lasting cellular dysfunction [4].
The evidence that inhibition of RAGE may be beneficial in
sepsis is derived from what is, thus far, a limited number of
studies. In a hallmark study published in 2004, Liliensiek and
colleagues [5] reported that RAGE-deficient mice were
strongly protected against lethality due to polymicrobial
sepsis caused by cecal ligation and puncture (CLP). The
protection provided by the lack of RAGE was associated with
a strongly reduced activation of NF-κB in the peritoneum and
lungs, which in wild-type mice was abundantly present,
suggesting that the absence of excessive NF-κB activation in
RAGE-deficient mice might have contributed to their reduced
mortality [5]. In addition, RAGE deficiency resulted in a
diminished accumulation of inflammatory cells in the
peritoneum, which is in line with an earlier investigation by the
same group of authors identifying RAGE as a counter-
receptor for the β2-integrin Mac-1 (CD11b/CD18) and
thereby as a mediator of leukocyte recruitment and adhesion
[6]. Moreover, other authors have demonstrated that RAGE-
deficient mice are partially protected against lethality due to
endotoxin shock [7]. It is likely that the protective effect of
RAGE inhibition in experimental sepsis is due, at least in part,
to inhibition of one of its ligands, HMGB1. Indeed, HMGB1 is
released in the circulation during experimental and clinical
sepsis and an anti-HMGB1 antibody protected against
endotoxin- and CLP-induced lethality [8,9]. Importantly,
HMGB1 can activate not only RAGE but also other
receptors, most notably Toll-like receptors 2 and 4 [3], and
anti-HMGB1 treatment caused an additional survival benefit
in RAGE-deficient mice injected with high-dose endotoxin,
suggesting that HMGB1 acts only partially via RAGE during
endotoxin shock [7].
Which questions remain to be answered to further establish a
role for RAGE in sepsis and to obtain further support for the
notion that RAGE may be a therapeutic target in this
syndrome? When addressing this question, one needs to
consider that the historic concept of the pathogenesis of
sepsis implicating mortality as the consequence of an
uncontrolled hyperinflammatory response of the host has
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been modified. The scientific community now agrees that this
paradigm is oversimplified and only partially true [10]. The
extent and duration of hyperinflammation likely vary due to
differences in the comorbidity, nutritional status, age, and
genetic background of the patient, on the one hand, and the
initial source of the infection, the virulence of the causing
organism, and the size of the infectious inoculum on the other
hand. In most if not all patients who survive the acute phase
of sepsis, a prolonged state of immune suppression evolves;
this condition is referred to as immunoparalysis [11].
Moreover, experimental studies have indicated that a certain
degree of inflammation is necessary to mount an effective
innate immune response to invading pathogens. As such,
RAGE inhibition may be ineffective or even harmful in some
infectious conditions. Therefore, more research is required to
situate RAGE in a position that warrants clinical trials in
patients with sepsis. In this respect, one could think of
studies on RAGE inhibition in pneumonia, considering that
the lung not only is the most frequent cause of sepsis in
humans [12] but also represents an organ in which RAGE is
abundantly expressed [13]. In addition, experiments in which
anti-RAGE treatment is delayed until after bacterial infection
(peritonitis and pneumonia) and combined with antibiotic
therapy should be considered. Moreover, more studies need
to be conducted on the role of RAGE in critical organ
derangements implicated in the pathogenesis of sepsis,
including activation of the coagulation system and the
complement system. Until then, RAGE remains a potential yet
promising therapeutic target in sepsis which awaits further
research.
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